

Remarks:

After entry of the amendment, claims 2, 14-16, 28-39, 55-57 and 59 are pending.

Claims 3-13, 17-27, 40-54 and 58 have been cancelled without prejudice or disclaimer.

Applicants retain the right to pursue the subject matter of these claims in future continuation or divisional applications.

Claim 55 has been editorially amended.

In claim 59 the definition of R₁ has been amended to comply with the Restriction Requirement for Group IV.

No issues of new matter should arise and entry of the amendment is respectfully requested.

A. Claim Objection

Claims 55-57 have been objected to because of informalities.

Claim 55 has been amended to correct the typographical error for “sulphonamide”. In view thereof, Applicants request that the objection be withdrawn.

B. Information Disclosure Statement filed October 14, 2005

Applicants respectfully request that the Examiner acknowledge the references cited on the Information Disclosure Statement filed October 14, 2005. A copy of the Information Disclosure Statement, PTO-1449 Form, and October 14, 2005, date-stamped filing receipt are attached hereto as Exhibit 1.

Conclusion

Applicants respectfully request reconsideration and allowance of claims 2, 14-16, 28-39, 55-57 and 59. Examiner Stockton is encouraged to contact the undersigned concerning any questions about the present application.

Respectfully submitted,

A handwritten signature in black ink that reads "Belinda M. Lew". The signature is written in a cursive, flowing style.

Belinda M. Lew, Ph.D.
Registration No. 53,212

Dated: January 9, 2006
Wilmer Cutler Pickering Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: 202-942-8449